drugset / Trial / NCT05999435

Study of LAU-7b for the Treatment of Long COVID in Adults

NCT05999435

Phase 2/3 Completed 272 enrolled Laurent Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.

Timeline

Start
2023-11-15
Primary completion
2024-08-05
Completion
2024-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject fenretinide Small molecule Oral

Indications